European Commission seeks biopharma feedback on Novo-Catalent deal — report

The Eu­ro­pean Com­mis­sion is ask­ing bio­phar­ma and man­u­fac­tur­ing com­pa­nies about their re­ac­tion to No­vo Hold­ings’ pro­posed ac­qui­si­tion of Catal­ent, ac­cord­ing to Reuters.

While the EC …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.